- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer
Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center, discusses findings from a real-world study investigating the effects of prior treatment, ESR1 mutation status, and PI3K pathway mutation status on outcomes with elacestrant (Orserdu) monotherapy in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer.
Related Content:
